Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | YAP1 | P46937 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29901843 | 1.00 | CCR9 (0.47) | CCR9GAASMN1; SMN2PDE4APDE4B | |
| SCHEMBL30411292 | 0.87 | BRD4 (0.41) | GAASMN1; SMN2TP53ALOX15ALDH1A1 | |
| SCHEMBL20766284 | 0.87 | BRD4 (0.41) | GAASMN1; SMN2TP53ALOX15ALDH1A1 | |
| SCHEMBL20767265 | 0.86 | ALOX15 (0.40) | GAAALOX15ALDH1A1HPGDHTT | |
| SCHEMBL29901835 | 0.86 | ALOX15 (0.40) | GAAALOX15ALDH1A1HPGDHTT | |
| SCHEMBL20766828 | 0.83 | ALOX15 (0.44) | CCR9GAAALOX15ALDH1A1KMT2A | |
| SCHEMBL20779794 | 0.81 | RAB9A (0.39) | CCR9GAASMN1; SMN2RXFP1TP53 | |
| SCHEMBL30411184 | 0.80 | GPR39 (0.47) | GAASMN1; SMN2TP53ALOX15ALDH1A1 | |
| SCHEMBL20766351 | 0.80 | GPR39 (0.47) | GAASMN1; SMN2TP53ALOX15ALDH1A1 | |
| SCHEMBL20766361 | 0.77 | PIK3CD (0.48) | SMN1; SMN2ALOX15ALDH1A1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| CN-111542315-B | Benzosulfonyl compounds | 维瓦斯治疗公司 | 2023-05-12 | — | — | CN | disclosed |
| EP-3691623-B1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS INC (US) | 2022-10-05 | — | — | EP | disclosed |
| US-11192865-B2 | Benzosulfonyl compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-11192865-B2 | Benzosulfonyl compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200354325-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-11-12 | — | — | US | disclosed |
| US-20200354325-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-11-12 | — | — | US | disclosed |
| CN-111542315-A | Benzosulfonyl compounds | 维瓦斯治疗公司 | 2020-08-14 | — | — | CN | disclosed |
| EP-3691623-A1 | BENZOSULFONYL COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019040380-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019040380-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192865-B2 | Benzosulfonyl compounds | YAP1, TEAD2, TEAD1 | CCR9 4497/4885GAA 3413/4885SMN1; SMN2 2357/4885 |
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | CCR9 1972/4885GAA 3205/4885SMN1; SMN2 3035/4885 |
| US-20200354325-A1 | BENZOSULFONYL COMPOUNDS | YAP1, TEAD2, TEAD1 | CCR9 4497/4885GAA 3413/4885SMN1; SMN2 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.